KR102797968B1 - 헤테로방향족 nmda 수용체 조절제 및 이의 용도 - Google Patents

헤테로방향족 nmda 수용체 조절제 및 이의 용도 Download PDF

Info

Publication number
KR102797968B1
KR102797968B1 KR1020217006300A KR20217006300A KR102797968B1 KR 102797968 B1 KR102797968 B1 KR 102797968B1 KR 1020217006300 A KR1020217006300 A KR 1020217006300A KR 20217006300 A KR20217006300 A KR 20217006300A KR 102797968 B1 KR102797968 B1 KR 102797968B1
Authority
KR
South Korea
Prior art keywords
compound
disorder
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217006300A
Other languages
English (en)
Korean (ko)
Other versions
KR20210039432A (ko
Inventor
로버트 에이. 볼크만
데이비드 알. 앤더슨
샘 말레키아니
티모시 피서
그렉 에프. 키니
스티븐 씨. 레이저
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20210039432A publication Critical patent/KR20210039432A/ko
Application granted granted Critical
Publication of KR102797968B1 publication Critical patent/KR102797968B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020217006300A 2018-08-03 2019-08-02 헤테로방향족 nmda 수용체 조절제 및 이의 용도 Active KR102797968B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862714100P 2018-08-03 2018-08-03
US62/714,100 2018-08-03
PCT/US2019/044814 WO2020086136A2 (en) 2018-08-03 2019-08-02 Heteroaromatic nmda receptor modulators and uses thereof

Publications (2)

Publication Number Publication Date
KR20210039432A KR20210039432A (ko) 2021-04-09
KR102797968B1 true KR102797968B1 (ko) 2025-04-22

Family

ID=69228330

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217006300A Active KR102797968B1 (ko) 2018-08-03 2019-08-02 헤테로방향족 nmda 수용체 조절제 및 이의 용도

Country Status (37)

Country Link
US (5) US10584131B2 (enExample)
EP (2) EP3830092B1 (enExample)
JP (1) JP7319369B2 (enExample)
KR (1) KR102797968B1 (enExample)
CN (1) CN112513047B (enExample)
AR (1) AR115905A1 (enExample)
AU (1) AU2019368147B2 (enExample)
BR (1) BR112021001967A2 (enExample)
CA (1) CA3108519A1 (enExample)
CL (1) CL2021000294A1 (enExample)
CO (1) CO2021002898A2 (enExample)
CR (1) CR20210125A (enExample)
CU (1) CU24647B1 (enExample)
CY (1) CY1126144T1 (enExample)
DK (1) DK3830092T3 (enExample)
DO (1) DOP2021000025A (enExample)
EA (1) EA202190431A1 (enExample)
EC (1) ECSP21014902A (enExample)
ES (2) ES2951872T3 (enExample)
FI (1) FI3830092T3 (enExample)
HR (1) HRP20230774T1 (enExample)
HU (1) HUE062566T2 (enExample)
IL (1) IL280474B2 (enExample)
JO (1) JOP20210020A1 (enExample)
LT (1) LT3830092T (enExample)
MA (1) MA53351B1 (enExample)
MX (1) MX2021001367A (enExample)
PE (1) PE20210948A1 (enExample)
PH (1) PH12021550242A1 (enExample)
PL (1) PL3830092T3 (enExample)
PT (1) PT3830092T (enExample)
RS (1) RS64359B1 (enExample)
SG (1) SG11202101125VA (enExample)
SI (1) SI3830092T1 (enExample)
TW (1) TWI833783B (enExample)
WO (1) WO2020086136A2 (enExample)
ZA (1) ZA202101273B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017100599A1 (en) 2015-12-09 2017-06-15 Luc Therapeutics Thienopyrimidinone nmda receptor modulators and uses thereof
ES2821010T3 (es) * 2015-12-09 2021-04-23 Cadent Therapeutics Inc Moduladores heteroaromáticos del receptor NMDA y usos de los mismos
AU2017382339B2 (en) 2016-12-22 2024-02-15 Novartis Ag NMDA receptor modulators and uses thereof
PT3830092T (pt) 2018-08-03 2023-07-25 Novartis Ag Moduladores do recetor nmda heteroaromáticos e suas utilizações
WO2025019109A1 (en) * 2023-07-17 2025-01-23 Neumora Therapeutics, Inc. Modulators of nmda receptors and related products and methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016081649A1 (en) 2014-11-18 2016-05-26 Emory University Thieno[2,3-d]pyrimidin-4-one derivatives as nmdar modulators and uses related thereto
WO2017100591A1 (en) 2015-12-09 2017-06-15 Luc Therapeutics Heteroaromatic nmda receptor modulators and uses thereof

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1067079A (en) 1976-07-22 1979-11-27 Yamanouchi Pharmaceutical Co. Nitrogen-containing heterobicyclic compounds
FR2549834B1 (fr) 1983-07-25 1985-10-18 Sanofi Sa Derives de triazolo-pyrimidine, leur procede de preparation et leur application therapeutique en tant que tonicardiaques
US4921854A (en) 1986-12-30 1990-05-01 Egis Gyogyszergyar Condensed thiazolopyrimidine, pyrimido-thiazine or thiazepine pyrimidine compounds
US5298502A (en) 1988-12-12 1994-03-29 Fmc Corporation Method and composition for photodynamic treatment and detection of tumors
AU6643694A (en) 1993-05-21 1994-12-20 Pentapharm Ag 3-(mercaptoalkyl)- or 3-(alkylthioalkyl)- pyrimidin-2,4(1h, 3h)-diones
JP2000513375A (ja) 1996-06-28 2000-10-10 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプター拮抗薬プロドラッグ
US6339093B1 (en) 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives
WO2002000629A1 (en) 2000-06-26 2002-01-03 Merck & Co., Inc. Iminopyrimidine nmda nr2b receptor antagonists
US6878743B2 (en) 2001-09-18 2005-04-12 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
AR038118A1 (es) 2002-01-14 2004-12-29 Upjohn Co Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
RU2378258C2 (ru) 2004-07-13 2010-01-10 Ф. Хоффманн-Ля Рош Аг Производные сульфонамида
TW200643015A (en) 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
NZ575426A (en) 2006-09-11 2010-09-30 Organon Nv Quinazolinone and isoquinolinone acetamide derivatives useful for the treatment of disorders which are influenced by modulation of the activity of the hpa axis
EP2066640B1 (en) 2006-09-11 2011-09-07 N.V. Organon 2-(1-oxo-1h-isoquinolin-2-yl) acetamide derivatives
JP5622393B2 (ja) 2006-12-15 2014-11-12 アブラクシスバイオサイエンス リミテッド ライアビリティー カンパニー トリアジン誘導体類及びそれらの治療応用
EP1939187A1 (en) 2006-12-20 2008-07-02 Sanofi-Aventis Substituted heteroaryl pyridopyrimidone derivatives
WO2008097538A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
JP5675341B2 (ja) 2007-04-18 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオキソキナゾリノン誘導体
WO2008138126A1 (en) 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
EP2190428A4 (en) 2007-08-21 2012-02-29 Merck Sharp & Dohme HETEROCYCLIC COMPOUNDS AS DIPEPTIDYLPEPTIDASE IV HEMMER FOR TREATMENT OR PREVENTION OF DIABETES
TW200934497A (en) 2007-11-13 2009-08-16 Organon Nv Heterocyclic derivatives
AU2009243006B2 (en) 2008-05-01 2013-03-21 Sirtris Pharmaceuticals, Inc. Quinolines and related analogs as sirtuin modulators
CN102112475A (zh) 2008-05-29 2011-06-29 西特里斯药业公司 作为沉默调节蛋白调节剂的咪唑并吡啶和相关的类似物
EP2138494A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted alkyl pyrimidin-4-one derivatives
BRPI0914006A2 (pt) 2008-07-03 2015-10-27 Sirtris Pharmaceuticals Inc benzimidazóis e análogos relacionados como moduladores de sirtuína
CN101628913B (zh) 2008-07-18 2013-01-23 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
CA2738794C (en) 2008-09-29 2016-01-05 Sirtris Pharmaceuticals, Inc. Chromenone analogs as sirtuin modulators
CA2747419C (en) 2009-01-12 2014-07-08 Icagen, Inc. Sulfonamide derivatives
WO2010111573A1 (en) 2009-03-27 2010-09-30 Abbott Laboratories Compounds as cannabinoid receptor ligands
EP2264035A1 (en) 2009-06-04 2010-12-22 Merz Pharma GmbH & Co. KGaA Glycine B antagonists
TW201116532A (en) 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
CN102666540A (zh) 2009-10-13 2012-09-12 Msd欧斯股份有限公司 用于治疗乙酰胆碱受体相关疾病的稠合吖嗪衍生物
US9290507B2 (en) 2010-03-26 2016-03-22 Boehringer Ingelheim International Gmbh B-RAF kinase inhibitors
EP2552907B1 (en) 2010-03-26 2014-10-22 Boehringer Ingelheim International GmbH Pyridyltriazoles
EP2593106A4 (en) 2010-07-16 2014-01-01 Univ Rockefeller ORGANIC CONNECTIONS
JP2013540145A (ja) 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤
US20120165330A1 (en) 2010-12-22 2012-06-28 Sirtris Pharmaceuticals, Inc. Quinazolinone and related analogs as sirtuin modulators
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2012154760A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
WO2013048928A1 (en) 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US8946430B2 (en) 2011-09-30 2015-02-03 Bristol-Myers Squibb Company Quinolinone carboxamide inhibitors of endothelial lipase
US8993557B2 (en) 2011-09-30 2015-03-31 Bristol-Myers Squibb Company Pyridinedione carboxamide inhibitors of endothelial lipase
CN102336768A (zh) 2011-10-24 2012-02-01 中国科学院上海有机化学研究所 N’-芳亚甲基-2-(4-氧代噻吩[2,3-d]嘧啶-3-基)乙酰腙类化合物、制备方法和用途
MX370976B (es) 2011-11-11 2020-01-10 Gilead Apollo Llc Inhibidores de acetil coa carboxilasa (acc) y usos de los mismos.
EP3406252B1 (en) 2012-02-10 2020-05-13 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
WO2014066743A1 (en) 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2014179144A1 (en) 2013-04-29 2014-11-06 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
WO2014206343A1 (en) 2013-06-28 2014-12-31 Beigene, Ltd. Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
WO2015007453A1 (en) 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
TW201609656A (zh) 2013-09-26 2016-03-16 美涅莫辛製藥公司 Ｎｒ２ａ之ｎ-芳基甲基磺醯胺負向調節劑
PT3055315T (pt) 2013-10-11 2018-10-25 Hoffmann La Roche Tiazolopirimidonas enquanto moduladores da atividade do recetor nmda
WO2015064714A1 (ja) 2013-10-31 2015-05-07 国立大学法人東京大学 オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体
CN103664877A (zh) 2013-12-25 2014-03-26 重庆医药工业研究院有限责任公司 一种喹啉衍生物、其制备方法和应用
WO2016034703A1 (en) 2014-09-05 2016-03-10 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
PE20180316A1 (es) 2015-04-15 2018-02-09 Hoffmann La Roche Compuestos piridopirimidinona y su uso como moduladores del receptor de nmda
KR20180102052A (ko) 2015-10-16 2018-09-14 노오쓰웨스턴 유니버시티 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용
WO2017100599A1 (en) 2015-12-09 2017-06-15 Luc Therapeutics Thienopyrimidinone nmda receptor modulators and uses thereof
US20170305861A1 (en) 2016-04-25 2017-10-26 Immunomet Therapeutics, Inc Heteroaryl compounds comprising nitrogen and use thereof
WO2018026371A1 (en) 2016-08-04 2018-02-08 Sunovion Pharmaceuticals Inc. Dual nav1.2/5ht2a inhibitors for treating cns disorders
AU2017382339B2 (en) 2016-12-22 2024-02-15 Novartis Ag NMDA receptor modulators and uses thereof
US10633387B2 (en) 2017-09-27 2020-04-28 Incyte Corporation Salts of TAM inhibitors
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
PT3830092T (pt) 2018-08-03 2023-07-25 Novartis Ag Moduladores do recetor nmda heteroaromáticos e suas utilizações

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016081649A1 (en) 2014-11-18 2016-05-26 Emory University Thieno[2,3-d]pyrimidin-4-one derivatives as nmdar modulators and uses related thereto
WO2017100591A1 (en) 2015-12-09 2017-06-15 Luc Therapeutics Heteroaromatic nmda receptor modulators and uses thereof

Also Published As

Publication number Publication date
CU20210013A7 (es) 2021-09-07
HRP20230774T1 (hr) 2023-10-27
EP4223760B1 (en) 2025-06-04
PT3830092T (pt) 2023-07-25
ECSP21014902A (es) 2021-05-31
CL2021000294A1 (es) 2021-06-18
TWI833783B (zh) 2024-03-01
SG11202101125VA (en) 2021-03-30
IL280474B2 (en) 2023-09-01
CR20210125A (es) 2021-06-30
TW202019932A (zh) 2020-06-01
US20240199617A1 (en) 2024-06-20
US10584131B2 (en) 2020-03-10
US20200039987A1 (en) 2020-02-06
ZA202101273B (en) 2023-05-31
CN112513047A (zh) 2021-03-16
MX2021001367A (es) 2021-06-23
US11542264B2 (en) 2023-01-03
HUE062566T2 (hu) 2023-11-28
KR20210039432A (ko) 2021-04-09
EP3830092A2 (en) 2021-06-09
FI3830092T3 (fi) 2023-07-21
ES2951872T3 (es) 2023-10-25
IL280474A (en) 2021-03-01
MA53351A (fr) 2022-01-12
EP4223760A1 (en) 2023-08-09
WO2020086136A2 (en) 2020-04-30
AR115905A1 (es) 2021-03-10
CU24647B1 (es) 2023-02-13
US20210403474A1 (en) 2021-12-30
EP3830092B1 (en) 2023-05-03
CA3108519A1 (en) 2020-04-30
EA202190431A1 (ru) 2021-06-11
IL280474B1 (en) 2023-05-01
PL3830092T3 (pl) 2023-11-13
CO2021002898A2 (es) 2021-05-31
JOP20210020A1 (ar) 2021-01-25
CY1126144T1 (el) 2023-11-15
US20250034145A1 (en) 2025-01-30
RS64359B1 (sr) 2023-08-31
BR112021001967A2 (pt) 2021-04-27
PE20210948A1 (es) 2021-05-24
DK3830092T3 (en) 2023-08-07
MA53351B1 (fr) 2023-08-31
PH12021550242A1 (en) 2021-11-29
JP7319369B2 (ja) 2023-08-01
US20200131190A1 (en) 2020-04-30
JP2021534227A (ja) 2021-12-09
AU2019368147A1 (en) 2021-03-18
CN112513047B (zh) 2023-10-20
WO2020086136A3 (en) 2020-08-06
SI3830092T1 (sl) 2023-09-29
AU2019368147B2 (en) 2024-05-30
ES3039982T3 (en) 2025-10-27
DOP2021000025A (es) 2021-05-31
LT3830092T (lt) 2023-09-11
US10752633B2 (en) 2020-08-25

Similar Documents

Publication Publication Date Title
JP7319369B2 (ja) ヘテロ芳香族ｎｍｄａ受容体モジュレーターおよびその使用
CA2640223A1 (en) Methods and compositions for treating schizophrenia
CN102088853A (zh) 改善学习和记忆的化合物
US20210253588A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
ES2784398T3 (es) Compuestos heterocíclicos de 3,3-difluoropiperidina carbamato como antagonistas del receptor de NMDA NR2B
WO2013120438A1 (zh) 治疗或缓解疼痛的物质
WO2016084866A1 (ja) 新規ジアザビシクロ誘導体
WO2014078377A1 (en) Methods and compositions for treating schizophrenia
EA035188B1 (ru) Терапевтические соединения
JP2018016544A (ja) 新規ジアザビシクロ［２．２．２］オクタン誘導体
IL256354B (en) Benzodiazepine derivatives, compositions, and uses thereof for treating cognitive impairment
CN107383002A (zh) 一类含氟三氮唑并吡啶类化合物及其制备方法、药物组合物和用途
CN110719779B (zh) 包含非外消旋比例的(r)-地来西坦(1)和(s)-地来西坦(2)的协同组合物
RU2800064C2 (ru) Гетероароматические модуляторы nmda-рецептора и их применение
HK40049118B (en) Heteroaromatic nmda receptor modulators and uses thereof
HK40049118A (en) Heteroaromatic nmda receptor modulators and uses thereof
EA040862B1 (ru) Гетероароматические модуляторы nmda рецептора и их применение
Sharmin Design, Synthesis, and Biological Evaluation of Gabaar Subtype Selective (α6, α2/3, and α5) Ligands to Treat Migraine, Neuropathic Pain, Trigeminal Pain, Tourette Syndrome, Epilepsy, Anxiety and Cognitive Disorders As Well As Asthma

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210302

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220801

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240925

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250320

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250415

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250416

End annual number: 3

Start annual number: 1

PG1601 Publication of registration